Market capitalization | $72.30m |
Enterprise Value | $25.64m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.55 |
P/S ratio (TTM) P/S ratio | 7.18 |
P/B ratio (TTM) P/B ratio | 1.58 |
Revenue growth (TTM) Revenue growth | 559.46% |
Revenue (TTM) Revenue | $10.07m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:
6 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
558%
558%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -13 -13 |
0%
0%
|
EBIT (Operating Income) EBIT | -13 -13 |
0%
0%
|
Net Profit | -12 -12 |
47%
47%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
Head office | United States |
CEO | John Alam |
Employees | 8 |
Founded | 2001 |
Website | www.cervomed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.